2-(4-ethylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide profile

ID Source	ID
PubMed CID	698942
CHEMBL ID	1373057
CHEBI ID	92064

Synonym
2-(4-ethylphenoxy)-n-4h-1,2,4-triazol-3-ylacetamide
smr000291670
MLS000684020
TIMTEC1_001816
OPREA1_117681
OPREA1_665440
MLS-0265844.0001 ,
HMS1539C12
BRD-K03704870-001-01-4
MLS002460489
2-(4-ethylphenoxy)-n-(1h-1,2,4-triazol-5-yl)acetamide
AKOS001673076
HMS2228I20
HMS3355F07
cid_698942
2-(4-ethylphenoxy)-n-(1h-1,2,4-triazol-5-yl)ethanamide
bdbm51412
CHEMBL1373057
SR-01000495481-1
sr-01000495481
CHEBI:92064
Q27163859

Class	Description
aromatic ether	Any ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Luciferase	Photinus pyralis (common eastern firefly)	Potency	13.4591	0.0072	15.7588	89.3584	AID588342
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	56.2341	0.1000	20.8793	79.4328	AID588453
ATAD5 protein, partial	Homo sapiens (human)	Potency	14.8920	0.0041	10.8903	31.5287	AID504466; AID504467
apical membrane antigen 1, AMA1	Plasmodium falciparum 3D7	Potency	19.9526	0.7079	12.1943	39.8107	AID720542
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	44.6684	0.7079	36.9043	89.1251	AID504333
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	39.8107	0.0355	20.9770	89.1251	AID504332
NPC intracellular cholesterol transporter 1 precursor	Homo sapiens (human)	Potency	3.1623	0.0126	2.4518	25.0177	AID485313
pyruvate kinase PKM isoform a	Homo sapiens (human)	Potency	8.9125	0.0401	7.4590	31.6228	AID1631; AID1634
flap endonuclease 1	Homo sapiens (human)	Potency	89.1251	0.1337	25.4129	89.1251	AID588795
ras-related protein Rab-9A	Homo sapiens (human)	Potency	4.4668	0.0002	2.6215	31.4954	AID485297
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	79.4328	0.0501	27.0736	89.1251	AID588590
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	0.8913	0.0079	8.2332	1,122.0200	AID2546
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	17.7828	0.1259	12.2344	35.4813	AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
alkaline phosphatase, tissue-nonspecific isozyme isoform 1 preproprotein	Homo sapiens (human)	EC50 (µMol)	4.1700	0.2270	25.0904	86.8000	AID1659
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay ID	Title	Year	Journal	Article
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (14.29)	29.6817
2010's	5 (71.43)	24.3611
2020's	1 (14.29)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1

2-(4-ethylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide

Cross-References

Synonyms (22)

Drug Classes (1)

Protein Targets (14)

Potency Measurements

Activation Measurements

Bioassays (15)

Research

Studies (7)

Market Indicators

Research Demand Index: 12.20

Study Types

2-(4-ethylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide

Cross-References

Synonyms (22)

Drug Classes (1)

Protein Targets (14)

Potency Measurements

Activation Measurements

Bioassays (15)

Research

Studies (7)

Market Indicators

Research Demand Index: 12.20

Study Types

Related Conditions (4)